A detailed history of Fiera Capital Corp transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Fiera Capital Corp holds 1,354,469 shares of APLS stock, worth $44.9 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares
1,354,469
Previous 1,401,190 3.33%
Holding current value
$44.9 Million
Previous $53.7 Million 27.33%
% of portfolio
0.12%
Previous 0.18%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

SELL
$28.84 - $41.15 $1.35 Million - $1.92 Million
-46,721 Reduced 3.33%
1,354,469 $39.1 Million
Q2 2024

Aug 01, 2024

BUY
$38.07 - $59.71 $17.2 Million - $27 Million
452,753 Added 47.74%
1,401,190 $53.7 Million
Q1 2024

Aug 22, 2024

SELL
$55.39 - $72.47 $25.1 Million - $32.8 Million
-452,753 Reduced 32.31%
948,437 $55.7 Million
Q1 2024

May 01, 2024

BUY
$55.39 - $72.47 $1.63 Million - $2.13 Million
29,347 Added 3.19%
948,437 $55.7 Million
Q4 2023

Aug 22, 2024

SELL
$37.14 - $64.82 $22,284 - $38,891
-600 Reduced 0.07%
919,090 $55 Million
Q4 2023

Feb 08, 2024

SELL
$37.14 - $64.82 $22,284 - $38,891
-600 Reduced 0.07%
919,090 $55 Million
Q3 2023

Aug 22, 2024

SELL
$23.65 - $89.22 $11.4 Million - $43 Million
-481,500 Reduced 34.36%
919,690 $35 Million
Q3 2023

Nov 09, 2023

BUY
$23.65 - $89.22 $9.27 Million - $35 Million
391,770 Added 74.21%
919,690 $35 Million
Q2 2023

Aug 09, 2023

SELL
$76.68 - $93.31 $955,586 - $1.16 Million
-12,462 Reduced 2.31%
527,920 $48.1 Million
Q1 2023

Apr 26, 2023

BUY
$46.59 - $66.96 $25.2 Million - $36.2 Million
540,382 New
540,382 $35.6 Million

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.64B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Fiera Capital Corp Portfolio

Follow Fiera Capital Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fiera Capital Corp, based on Form 13F filings with the SEC.

News

Stay updated on Fiera Capital Corp with notifications on news.